C
rohn's disease (CD) is a chronic inflammatory disease that can affect any part of the gastrointestinal tract, although it most often affects the terminal ileum and proximal colon. Despite advances in drug treatment, around 25% to 61% of patients with CD require intestinal resection owing to complications related to stenosis or penetrating disease. 1, 2 The postoperative recurrence (POR) rate varies according to the definition used, be it clinical, endoscopic, radiological, or surgical. POR is lower when measured based on clinical indices and higher when based on endoscopy findings. Hence, in population-based studies, the clinical POR rate ranged from 28% to 45% and from 36% to 61% at 5 and 10 years, respectively. It has been demonstrated that the postoperative clinical course of CD is best predicted by the severity of endoscopic lesions 3 ; therefore, endoscopic surveillance performed between 6 months and 1 year after surgery is crucial for the early detection of POR. Furthermore, endoscopic surveillance of patients after bowel resection with ileocolonic anastomosis reveals that 70% experience the development of new mucosal lesions at the site of the anastomosis or proximal to it if no preventive measures are taken, a phenomenon known as POR. 3, 4 Endoscopic POR may appear 6 months after surgery and generally precedes clinical POR. 5 The recent European evidence-based consensus on the management of postoperative CD considers ileocolonoscopy the gold standard for the diagnosis of POR by defining the presence and severity of morphologic recurrence and predicting the clinical course. Therefore, this approach is recommended within the first year after surgery, when treatment decisions may be affected. 6 Clinical management of CD after ileocolonic resection includes smoking cessation, as smokers have a 2.5-fold increased risk for surgical POR within 10 years, 7, 8 and prophylaxis in patients with at least 1 risk factor for POR. 9 To prevent POR, the European Crohn's and Colitis Organisation (ECCO) guidelines suggest that the drugs of choice are thiopurines or anti-tumor necrosis factor (TNF) agents. High-dose mesalamine is an option for patients who undergo isolated ileal resection, and imidazoles have been shown to be effective in the short term after ileocolic resection, although they are less well tolerated and should not be used as long-term prophylaxis.
This study was based on real-world clinical data and aimed to explore the incidence and management of POR of CD after intestinal resection in Spain.
MATERIALS AND METHODS
Practicrohn was a retrospective study performed in 26 inflammatory bowel disease (IBD) units throughout Spain. The clinical records were the main source of information. No data were collected prospectively.
Selection of Participants
The study population comprised consecutive patients from IBD outpatient clinics aged $18 years who underwent CD-related ileocolonic resection with ileocolonic or ileorectal anastomosis between January 2007 and December 2010. Data were collected from the time of diagnosis of CD and up to 5 years after surgery. When a patient underwent more than 1 procedure, the index surgery was defined as that performed closest to December 2010. The data collected included demographics (age, sex, smoking status, and family history), clinical data (date of diagnosis, Montreal classification, extraintestinal manifestations, and immunemediated inflammatory diseases), treatments received, number of previous surgeries, reason for current surgery (penetrating disease, stricturing disease, or resistance to treatment), and length of resection. Data regarding prophylaxis, deaths, clinical symptoms of recurrence, endoscopic results, imaging techniques (computed tomography and magnetic resonance imaging), hospitalizations, and reoperations were collected yearly until 5 years after surgery.
In the case of prophylaxis for POR, the analysis was based on the most potent drug, with anti-TNF agents defined as the most potent (with or without other drugs) followed by immunomodulators (alone or in combination with antibiotics or mesalamine), antibiotics (alone or with mesalamine), and finally mesalamine alone.
Clinical POR was defined as suggestive clinical symptoms (diarrhea and abdominal pain), or the presence of an abdominal mass and one of the following: endoscopic Rutgeerts score $i2, and/or confirmation of disease activity by computed tomography or magnetic resonance imaging performed within 6 months of symptoms.
Statistical Analysis
Based on previous studies showing 52-week endoscopic POR rates ranging from 36% to 56%, 10 for an endoscopic POR rate of 50%, assuming a confidence level (level 1-a) of 95% and an accuracy of 6%, the sample size required for the analysis was 267 patients. The sample size was increased by 15% (up to 314 individuals) to provide for exclusion because of incomplete data or for other reasons. The association between qualitative variables was studied using the chi-square test or Fisher's exact test (if more than 25% of the expected values were less than 5). Probability and relative risk were assessed along with the 95% confidence interval using an exact method. Missing values and their frequency were tabulated but not included in the calculation of percentages. In all cases, the distribution of the variables according to theoretical models was verified using the Kolmogorov-Smirnov test, and the assumption of homogeneity of variance was assessed using the Levene test.
Logistic regression analysis was performed to assess factors associated with POR. Variables with a P value of ,0.15 in the univariate analysis were selected for the multivariate analysis. The null hypothesis was rejected when P , 0.05. POR-free survival was assessed by means of Kaplan-Meier estimate of survival and log-rank test (or the Peto & Peto test).
Ethical Considerations
All study patients signed an informed consent form authorizing the use of their clinical data for research purposes. The study was approved by the local ethics committees.
RESULTS

Sample Characteristics
The study population comprised 314 patients: 151 men (48%) and 163 women (52%), with a median (interquartile range) age at diagnosis of 28.5 (22-41) years. Of these patients, 115 (37%) were smokers at the time of surgery. Forty (35%) had quit after 5 years of follow-up: of these, 23 quit (57%) during the first year, and 7 (17%), 7 (17%), and 3 (7%) quit at 2, 3, and 5 years after surgery, respectively. The median disease duration from diagnosis to surgery was 6 (1-12) years, and median age at resection was 38 (30-48) years. A total of 53 patients (17%) had previously undergone surgery. The indication for the index procedure was stricturing disease in 147 cases (48%), penetrating disease in 98 (32%), stricturing+penetrating disease in 46 (15%), and refractoriness to medical treatment in 14 (4%). Length of resection was #50 cm in 214 patients (87%) and .50 cm in 36 patients (13%). Penetrating disease was recorded in 128 (41%) patients at surgery. Table 1 shows the demographic and clinical characteristics of the sample at diagnosis and at surgery.
Between diagnosis and surgery, 226 patients (74%) had received corticosteroids, 196 (63%) had received immunomodulators, and 94 (30%) biologics. Treatments from diagnosis to surgery are summarized in Table 2 .
Follow-up After Surgery
After surgery, 208 patients (68%) received medication to prevent POR. Table 3 shows the prophylaxis administered at the time of discharge or first visit according to the most potent drug prescribed. Prophylactic treatment was prescribed in 56% in patients without risk factors, and in 75% in patients with 1 or more risk factors (P ¼ 0.02). There was no difference in prophylaxis after surgery by age, smoking habit at surgery, disease behavior, 
127 ( perianal disease, or extraintestinal manifestations. Similarly, there was no difference in prophylaxis in patients with previous surgery versus first surgery (P ¼ 0.12). Patients who received immunomodulators or biologic agents at surgery were prescribed significantly more prophylaxis after surgery (P , 0.001 and P ¼ 0.001, respectively), as were patients with bowel resection #50 cm (P ¼ 0.030). Endoscopy was performed in 143 (46%) patients during the first year after surgery. Additional analysis showed that in 2007, only 24 of 75 patients (32%) underwent endoscopy in the first year, whereas in 2010, endoscopy was performed in 47 of 79 (59%) (P ¼ 0.017). The trend for performance of endoscopy is shown in Figure 1 . Tables 4 and 5 show endoscopic findings during the first year and at 5 years of follow-up according to the Rutgeerts endoscopic score in patients who received and did not receive prophylaxis. More endoscopies were performed owing to symptoms of POR during the first year of follow-up in patients who did not receive prophylaxis (P ¼ 0.048). The percentage of endoscopies was similar in patients with and without risk factors. Treatment was modified more frequently each year in patients who did not receive prophylaxis than in those who did (P ¼ 0.038 at year 1, P ¼ 0.002 at year 2, P ¼ 0.004 at year 3, and P ¼ 0.010 at year 5). During the first year after surgery, 51 patients (16%) underwent computed tomography. In 7 (2%), the scan was programmed after discharge, and in 44 (14%), it was performed owing to symptoms of CD activity. Magnetic resonance enterography was performed in 30 (10%) patients during the first year after surgery. This was scheduled in 8 (2%), and in 22 (7%), it was performed because of CD activity or complications.
Clinical POR
During the 5-year follow-up, 97 patients (31%) met the criteria for clinical POR. Median time to clinical POR was 315 (165-748) days. The cumulative probability of clinical POR was 16%, 27%, and 31% at 1, 3, and 5 years, respectively. Clinical POR was 27% (56/199) in patients who received prophylaxis and 39% (39/94) for those who had not (P ¼ 0.033) (Fig. 2A) . Recurrence-free survival was higher in patients who received prophylaxis with immunomodulators (median not reached) than in those who did not receive prophylaxis (1529 median days) (P ¼ 0.014) (Fig. 2B) .
The multivariate analysis revealed that independent risk factors for clinical POR were smoking after surgery (P ¼ 0.029), upper gastrointestinal involvement of CD (P ¼ 0.018), inflammatory disease behavior (P ¼ 0.024), and endoscopy during the first year (P , 0.001), whereas prophylactic therapy with immunomodulators was an independent protective factor (P ¼ 0.003).
Hospitalizations and Reinterventions
During follow-up, 56 patients (18%) required at least 1 hospitalization during the first year, with a median stay of 10 (6-15) days. The reasons for hospitalization were as follows: POR or active disease in 36 patients (45%), surgery-related complications in 35 (44%), infection in 1 (1%), and other reasons in 7 (9%). At 5 years, 94 patients (30%) had been admitted to hospital, mostly because of disease activity. Reoperation was necessary in 45 patients (14%) within 5 years, mainly during the first year (n ¼ 23, 7%), and the most common reason was complication of previous surgery (n ¼ 18, 5%). The median time to first reoperation was 228 (133-527) days. At year 5, 22 patients had to undergo further surgery owing to CD activity, the most common reason being fistulae (n ¼ 11, 3%). No differences were found in the 5-year surgical POR rate regardless of whether the patient had received prophylaxis. 
DISCUSSION
In this study, we evaluated the postsurgical management of CD in a large real-world cohort comprising patients from hospitals throughout Spain. Approximately two-thirds of patients received prophylaxis for POR after surgery, and one-third experienced clinical POR during the 5-year follow-up. The recent ECCO guidelines recommend prophylaxis after ileocolonic intestinal resection to prevent POR in patients with at least 1 risk factor. In our study, two-thirds of patients received prophylaxis for recurrence. The most common regimen was immunomodulators in monotherapy or in combination with antibiotics or mesalamine, thus reflecting adherence to clinical guidelines. 9 In most controlled studies, the primary endpoint is endoscopic but not clinical POR. In our study, clinical POR was recorded in 97 (31%) patients at 5 years, and the Kaplan-Meier curves for clinical POR-free survival showed a significantly lower rate of POR in patients who received prophylaxis than in those who did not (P ¼ 0.033) and in patients who received prophylaxis with immunomodulators than in those who did not (P ¼ 0.014). No effect was observed for antibiotics or mesalamine on clinical POR or of adding antibiotics to immunomodulators. Published data revealed heterogeneous information on clinical POR depending on whether the sources consulted were population-based studies, referral centers, or clinical trials. In their population-based study of 173 patients who underwent surgery, Krause et al 11 recorded clinical POR in 52% after a follow-up of more than 14 years. In a population-based cohort study of 907 patients with primary ileocecal CD, Bernell et al 12 found clinical POR rates to be 28% and 36% at 5 and 10 years after the first resection, respectively. Similarly, Ng et al 13 reported data from a referral IBD center on 99 patients, 50% of whom were followed for 1 year after surgery. Clinical POR was recorded in 9 of 28 patients (32%) who had not received postsurgical medical therapy and in 19 of 71 (26%) who had (P ¼ NS). Reoperation was necessary in 5% of patients. Similarly, in a study of 40 patients followed prospectively in an IBD unit, Onali et al 14 POR during the 5-year follow-up, 4 patients were treated with anti-TNF agents, and 1 patient with azathioprine. Our data are more encouraging, probably because we more frequently administered prophylaxis, thus supporting the recommendations of scientific societies in a real-world setting. Finally, data from randomized controlled trials showed that approximately onequarter of patients experienced clinical POR, whereas around half experienced endoscopic POR during the first year after surgery. 15 ,16 D'Haens et al 17 published the results of a randomized clinical trial including 81 patients. The authors found that azathioprine was more effective than placebo when added to metronidazole, with endoscopic POR observed in 14 of 32 patients (43.7%) in the azathioprine group and in 20 of 29 patients (69.0%) in the placebo group at 12 months after surgery (P ¼ 0.048). The authors also found that the prevalence of clinical POR was rather low (8.5% in the azathioprine group and 18% in the placebo group), probably because all patients received 3 months of antibiotic therapy. Although some studies have shown a protective effect of ornidazole 16 and metronidazole 15 on clinical and endoscopic POR after curative ileocolonic resection, a pilot study of 50 patients who received 15 to 20 mg/kg of metronidazole added to azathioprine showed a nonsignificant trend toward benefit in clinical or endoscopic POR at 1 year 10 In our study, 28 patients were prescribed immunomodulators combined with antibiotics, and a further 2 patients received immunomodulators combined with antibiotics and mesalamine. The addition of antibiotics or mesalamine to immunomodulators gave no additional benefit over immunomodulators alone on clinical POR-free survival (P ¼ 0.06), and treatment with antibiotics or mesalamine alone had no effect on clinical POR-free survival compared with patients who did not receive prophylaxis (P ¼ 0.8 and 0.3, respectively). We confirmed the protective effect of immunomodulators on both clinical and endoscopic POR and support immunomodulators as the preferred drug for postsurgical prophylaxis. The small number of patients treated with anti-TNF after surgery (3 patients) could be explained by the fact that, at the time the study was performed, there was less evidence of the efficacy of anti-TNF agents for prevention of POR, although were unable to determine the effect of such treatment on clinical POR. A recent study 18 on the role of infliximab for prevention of clinical and endoscopic POR of CD after ileocolonic resection showed that infliximab was not superior to placebo in preventing clinical POR after CD-related resection. However, infliximab did reduce endoscopic POR (30.6% versus 60.0%; P , 0.001). Consistent with the findings of our literature review, the role of prophylactic mesalamine in our study seems to be of no benefit.
In this sample, scheduled endoscopy was performed in 143 (46%) patients during the first year after surgery. As our study was performed between 2007 and 2010, when the ECCO guidelines on management of CD had not yet been published, the small percentage of planned endoscopies in 2007 may be explained by the lack of clear recommendations, although the marked increasing trend toward more endoscopic evaluations in 2010 could indicate that current data would be even more favorable. A total of 262 patients (83%) underwent endoscopy during the 5 years after hospital discharge. The ileum was visualized in 224 patients (85%). Of these, 122 (54%) had endoscopic POR of CD, defined as a Rutgeerts endoscopic score $2. Similarly, our study revealed a statistically significant lower Rutgeerts endoscopic score after only 1 year of follow-up in patients who received prophylaxis than in those who did not (P ¼ 0.037). The prospective study by Orlando et al, 5 performed between 2005 and 2010, in which endoscopic POR was observed in 105 patients (62%) 6 months after surgery, suggests that if postsurgical endoscopy is performed at 6 months instead of 1 year, treatment could be escalated earlier in most cases of recurrence, as recently demonstrated elsewhere. 19 The association between endoscopy performed during the first year and more frequent clinical POR has 2 possible explanations: first, endoscopy is performed in high-risk patients; and second, endoscopy is performed when symptoms appear and are confirmatory of clinical POR.
Although the current study population may be considered high risk in that they had undergone at least 1 operation, of the 115 patients (36%) who smoked at the time of surgery, only 30 (26%) quit smoking during the first and second year after surgery. In their meta-analysis, Reese et al 7 found smoking to be a poor prognostic factor for clinical POR: a 2-fold increase in clinical POR was recorded in smokers compared with nonsmokers, as was a 2.5-fold increase in the risk of further surgery before 10 years. Therefore, the ECCO guidelines stress that all patients with CD should be informed of the risks associated with smoking and that cessation should be encouraged. Patients who continue to smoke should be treated as high risk and more closely monitored. We found no difference in prophylaxis strategies between smokers and nonsmokers; however, clinical POR was higher in smokers, thus supporting smoking as a risk factor.
A review article of risk factors for POR revealed that, in addition to smoking, the main risk factors were penetrating behavior, perianal disease, and extensive bowel disease (.50 cm). 4 Our data strongly support these findings because the multivariate analysis revealed that upper gastrointestinal involvement and inflammatory disease behavior were also independent risk factors for recurrence. We found no differences in POR with respect to length of resection, maybe because most of the patients (87%) underwent resections #50 cm.
Our study revealed a 14% probability of reintervention at 5 years, with a median time for reintervention of 228 days, the main reason being complications of surgery. In the county of Copenhagen, Denmark, Binder et al 20 reported that the 13% of patients who needed surgery had 2 or more operations within 10 years. A subsequent study from the same area reported that the cumulative probability of operation 15 years after the diagnosis of CD was 70%, 21 both studies reflecting disease management in an era where no prophylactic treatment was routinely prescribed after surgery. A retrospective study from a Swiss IBD cohort comprising 305 patients with CD followed for 15 years found that reintervention was necessary in 80 of 305 patients (26%), with resection of ileal disease identified as a risk factor for reintervention and immunomodulators within 1 year after intervention as a protective factor. 22 In our study, no difference in disease behavior was associated with more reinterventions.
Ours is the largest real-world study to reflect the clinical management of CD after surgery in a European country and to fully describe clinical practice without the potential bias of a prospective study. Its size and the length of follow-up faithfully reflect clinical practice in Spain. In addition, all patients underwent surgery during a short period (2007) (2008) (2009) (2010) , thus strengthening the validity of our results. We gathered data on both clinical and endoscopic POR, and our results on the effect of postsurgical prophylaxis on POR-free survival support the recommendations of the recent ECCO guidelines. The main limitations of the study are those inherent to retrospective studies. The patients had already been grouped, baseline measurements had already been made, the follow-up period had ended, and the researcher had limited control of the method of population sampling and the nature and quality of variables. Nevertheless, this design is the only one that enabled us to study clinical practice without the bias of a prospective approach.
In conclusion, our data support the role of smoking, location, and disease behavior as risk factors for clinical POR and the protective effect of prophylactic treatment with immunomodulators. Nevertheless, it revealed several areas of clinical practice that could be improved. First, the number of patients who receive prophylaxis after surgery and the proportion of patients who undergo endoscopy at the end of the first year are not optimal. Second, the incidence of clinical POR confirmed by endoscopy or imaging tests in clinical practice was approximately 30% within the first 5 years after surgery. Finally, every effort must be made to encourage patients to quit smoking after surgery.
